Key facts
- This page summarizes Emmett Cunningham's Form 4 filing for Galera Therapeutics, Inc. (GRTX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 16 Jun 2023, 16:15.
Emmett Cunningham - 14 Jun 2023 Form 4 Insider Report for Galera Therapeutics, Inc. (GRTX)
- Reporting relationship
- Director
- Issuer ticker
- GRTX
- Reported as of
- 14 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Jun 2023, 16:15:10 UTC
- Prior SEC filing
- 16 Jun 2022
- Next SEC filing
- 18 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Emmett Cunningham
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Emmett Cunningham filed Form 4 for Galera Therapeutics, Inc. (GRTX) on 16 Jun 2023.
Change
- Previous filing in this sequence was filed on 16 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GRTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +48,000
- Change %
- Price
- $0.000000*
- Shares after
- 0
- Date
- 14 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 48,000
- Exercise price
- $3.27
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This option shall vest and become exercisable on the earlier of June 14, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date.
Footnote F2
The Reporting Person disclaims beneficial ownership of these securities and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose. The Reporting Person is an employee of Blackstone Inc. or one of its affiliates ("Blackstone"). Pursuant to arrangements between the Reporting Person and Blackstone, the Reporting Person is required to transfer to Blackstone any and all compensation received in connection with his directorship for any company Blackstone invests in or advises.
SEC remarks
Dr. Cunningham, an employee of an affiliate of Blackstone, is a member of the board of directors of the issuer. Dr. Cunningham disclaims beneficial ownership of any securities of the issuer that may be deemed to be beneficially owned by affiliates of Blackstone.